Fidelity MSCI Health Care Index ETFFHLC

Fidelity’s MSCI Health Care Index ETF (FHLC) is a rules-based tracker of the MSCI USA IMI Health Care Index, a broad basket that spans pharmaceutical giants, biotech upstarts, and the companies behind the disposable gloves in your doctor’s office. The fund’s mandate is straightforward: hold every listed healthcare stock in the US investable market index, minus the bits that aren’t liquid or investable. That’s not a critique of the mandate; it’s just a reminder that the fund’s portfolio is as diverse as a hospital waiting room on flu season. The issuer’s marketing leans heavily on the sector’s innovation narrative, but the fund itself is a blunt instrument-cheap, broad, and designed to deliver the market return of healthcare minus the issuer’s 0.08% annual toll.

The fund trades on Nasdaq under the ticker FHLC, where its liquidity profile sits somewhere between a blue-chip stock and a mid-cap ETF. The SEC filing confirms the fund’s structure as an open-end management investment company under the Investment Company Act of 1940, meaning it’s subject to the same disclosure rigour as every other registered fund in America. That rigour doesn’t extend to the glamour of the portfolio; FHLC’s holdings are as exciting as a spreadsheet of drug codes and medical device classifications. The issuer’s fee is disclosed in the prospectus and on the fact sheet, but the real fee isn’t the 0.08%-it’s the opportunity cost of not seeing the portfolio’s composition until you dig into the holdings report.

The fund’s expense ratio is 0.08%, a figure that looks like a rounding error until you remember that Fidelity’s scale means it can absorb such costs while still turning a profit. The FINRA Fund Analyzer confirms the fee and the fund’s classification, but it doesn’t tell you whether the fund’s tracking difference will widen when the healthcare sector’s volatility spikes. The fund’s AUM and liquidity figures aren’t parsed in the supplied evidence, so any claim about its trading volume or market impact would be speculation. What is clear is that FHLC is a beta play on US healthcare, not a stock-picking vehicle.

The fund’s tracking method is full replication, meaning it aims to hold every constituent of the MSCI USA IMI Health Care Index in the same weights. That’s a sensible approach for a broad index ETF, but it also means the fund’s performance will hew closely to the index’s returns, whatever they may be. The MSCI index itself is a market-cap-weighted beast, so FHLC’s top holdings will mirror the index’s top weights-likely large pharmaceuticals, biotech firms, and managed-care companies. The issuer’s marketing will dress these holdings in innovation language, but the portfolio is still a collection of stocks whose collective fate is tied to everything from FDA decisions to the annual flu season.

The chart route for FHLC is available on Nasdaq, but the supplied evidence doesn’t include any price levels, volume data, or performance history. Without that, any attempt to analyse the fund’s recent moves would be guesswork. The fund’s structure, mandate, and fee are public; its price action is not. If you’re looking for a healthcare sector bet that’s cheap and broad, FHLC delivers. If you’re looking for a fund that will relative strength its index or dodge the sector’s volatility, the evidence doesn’t support that claim.